Targeting SARS-CoV-2 Main Protease for Treatment of COVID-19: Covalent Inhibitors Structure–Activity Relationship Insights and Evolution Perspectives

[Image: see text] The viral main protease is one of the most attractive targets among all key enzymes involved in the SARS-CoV-2 life cycle. Covalent inhibition of the cysteine(145) of SARS-CoV-2 M(PRO) with selective antiviral drugs will arrest the replication process of the virus without affecting...

Descripción completa

Detalles Bibliográficos
Autores principales: La Monica, Gabriele, Bono, Alessia, Lauria, Antonino, Martorana, Annamaria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2022
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528073/
https://www.ncbi.nlm.nih.gov/pubmed/36169610
http://dx.doi.org/10.1021/acs.jmedchem.2c01005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528073/
https://www.ncbi.nlm.nih.gov/pubmed/36169610
http://dx.doi.org/10.1021/acs.jmedchem.2c01005

Ejemplares similares